Tamsulosin
- Generic Name
- Tamsulosin
- Brand Names
- Flomax, Jalyn
- Drug Type
- Small Molecule
- Chemical Formula
- C20H28N2O5S
- CAS Number
- 106133-20-4
- Unique Ingredient Identifier
- G3P28OML5I
- Background
Tamsulosin is a selective alpha-1A and alpha-1B adrenoceptor antagonist that exerts its greatest effect in the prostate and bladder, where these receptors are most common. It is indicated for the treatment of signs and symptoms of benign prostatic hypertrophy. Antagonism of these receptors leads to relaxation of smooth muscle in the prostate and detrusor mus...
- Indication
Tamsulosin is indicated for the treatment of signs and symptoms of benign prostatic hyperplasia.
Tamsulosin is also used off label for the treatment of ureteral stones, prostatitis, and female voiding dysfunction.
- Associated Conditions
- Benign Prostatic Hyperplasia (BPH), Benign Prostatic Hypertrophy, Bladder Outlet Obstruction, Ureteral Calculus
- Associated Therapies
- -
Comparative Efficacy of Dutasteride Plus Tamulosin With Lifestyle Advice Versus Watchful Waiting Plus Lifestyle Advice in the Management of Treatment naïve Men With Moderately Symptomatic Benign Prostatic Hyperplasia and Prostate Enlargement
- Conditions
- Interventions
- First Posted Date
- 2011-02-11
- Last Posted Date
- 2018-08-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 742
- Registration Number
- NCT01294592
- Locations
- 🇬🇧
GSK Investigational Site, High Heaton, Newcastle Upon Tyne, United Kingdom
Effects of the Use of Adjuvant Drugs After Extracorporeal Shockwave Lithotripsy (ESWL) in Renal Calculus
- First Posted Date
- 2010-10-06
- Last Posted Date
- 2010-10-06
- Lead Sponsor
- University of Sao Paulo General Hospital
- Target Recruit Count
- 136
- Registration Number
- NCT01215708
- Locations
- 🇧🇷
Clinics Hospital of University of Sao Paulo, Sao Paulo, Brazil
Efficacy And Safety Study Of Naftopidil to Patients Treatment With LUTS
- First Posted Date
- 2010-09-16
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Apsen Farmaceutica S.A.
- Registration Number
- NCT01203371
- Locations
- 🇧🇷
Hospital das Clínicas da Faculdade de Medicina da USP, São Paulo, Brazil
Tamsulosin Hydrochloride 0.4 mg Capsules Under Fasting Conditions
- First Posted Date
- 2010-06-23
- Last Posted Date
- 2010-06-23
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 32
- Registration Number
- NCT01149746
- Locations
- 🇨🇦
Pharma Medica Research Inc., Toronto, Ontario, Canada
Tamsulosin Hydrochloride 0.4 mg Capsules Under Fed Conditions
- First Posted Date
- 2010-06-23
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 32
- Registration Number
- NCT01149733
- Locations
- 🇨🇦
Pharma Medica Research Inc., Toronto, Ontario, Canada
Medication Effects on Periurethral Sensation,Urethral Sphincter Activity and Pressure Flow Parameters
- Conditions
- Interventions
- First Posted Date
- 2009-12-09
- Last Posted Date
- 2012-06-08
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 56
- Registration Number
- NCT01028014
- Locations
- 🇺🇸
University of Alabama at Birmingham, The Kirklin Clinic, Birmingham, Alabama, United States
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia
- Conditions
- Interventions
- First Posted Date
- 2009-09-02
- Last Posted Date
- 2012-03-12
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 511
- Registration Number
- NCT00970632
- Locations
- 🇵🇱
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Warsaw, Poland
Clinical Effect and Safety of Tamsulosin 0.4mg in Patients With LUTS/BPH Refractory to Tamsulosin 0.2mg
- First Posted Date
- 2009-08-07
- Last Posted Date
- 2011-11-01
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 220
- Registration Number
- NCT00954889
- Locations
- 🇰🇷
Department of Urology, Samsung Medical Center, Seoul, Korea, Republic of
Efficacy Study of Tamsulosin and Tolterodine Treatment for Chronic Prostatitis
- First Posted Date
- 2009-06-04
- Last Posted Date
- 2009-06-05
- Lead Sponsor
- Chongqing Medical University
- Target Recruit Count
- 30
- Registration Number
- NCT00913315
- Locations
- 🇨🇳
Department of Urology, the First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China
Multinational Study to Evaluate Tadalafil in Asian Men With Signs and Symptoms of Benign Prostatic Hyperplasia
- Conditions
- Interventions
- First Posted Date
- 2009-03-13
- Last Posted Date
- 2011-06-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 612
- Registration Number
- NCT00861757
- Locations
- 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tao-Yuan, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.